Caxton Associates (UK)’s ATRenew RERE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$95.6K Sell
24,708
-50,213
-67% -$223K ﹤0.01% 728
2026
Q1
$351K Buy
+74,921
New +$422K 0.01% 569
2025
Q4
– Sell
-136,078
Closed -$626K – 936
2025
Q3
$626K Buy
+136,078
New +$548K 0.01% 417
2025
Q2
– Sell
-38,746
Closed -$114K – 869
2025
Q1
$114K Buy
+38,746
New +$114K ﹤0.01% 734

Other funds holding RERE

Caxton Associates (UK)'s RERE Position: Q2 2026 in Review

Caxton Associates (UK) reduced its ATRenew (RERE) stake by 67% in Q2 2026, selling an estimated $223K and leaving 24,708 shares worth $95.6K. The position accounts for ﹤0.01% of the portfolio, ranked #728.

Caxton Associates (UK) first reported a position in RERE in Q1 2025 and has held it in 4 quarters since. The position peaked at $626K in Q3 2025. 75 funds tracked by Wall St. Rank hold RERE as of Q2 2026.

  • Caxton Associates (UK) held 24,708 shares of ATRenew worth $95.6K as of Q2 2026.
  • Caxton Associates (UK) sold 50,213 ATRenew shares in Q2 2026, an estimated $223K.
  • ATRenew made up ﹤0.01% of Caxton Associates (UK)'s portfolio in Q2 2026, its #728 holding.
  • Caxton Associates (UK) first reported a position in ATRenew in Q1 2025 and has held it in 4 quarters since.
  • Caxton Associates (UK)'s ATRenew position peaked at $626K in Q3 2025.
  • 75 funds tracked by Wall St. Rank held ATRenew as of Q2 2026.

Based on Caxton Associates (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.